Skip to content

MaxCyte MXCT Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$39.12M+12.3%-$44.63M+2.2%-$45.63M-1.9%-$44.77M-7.1%-$41.79M-1.8%
$4.29M-1.1%$4.34M+0.3%$4.33M+0.1%$4.32M+0.4%$4.3M-0.3%
$7.32M-20.6%$9.21M-20.9%$11.64M-10.8%$13.06M-0.4%$13.11M+0.2%
-$28.17M+18.1%-$34.41M+13.0%-$39.54M-8.4%-$36.48M-16.0%-$31.46M-13.9%
$1.19M-32.9%$1.77M+5.0%$1.68M-5.9%$1.79M+19.3%$1.5M-9.1%
$19.06M-26.5%$25.94M
$278K-57.6%$656K-31.9%$963K-18.2%$1.18M-32.2%$1.74M-15.6%
-$23.99M-7.6%-$22.29M
-$29.36M+18.9%-$36.18M+12.2%-$41.23M-7.7%-$38.27M-16.1%-$32.96M-12.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does MaxCyte generate?
MaxCyte (MXCT) generated -$28.2M in operating cash flow over the trailing twelve months.
What is MaxCyte's free cash flow?
After $1.2M of capital expenditures, MaxCyte's free cash flow was -$29.4M over the trailing twelve months, up 10.9% year over year.
Where does MaxCyte's cash flow data come from?
Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.